Skip to main content
ACTUATE THERAPEUTICS, INC. logo

ACTUATE THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ACTU ISIN · US0050831009 US Manufacturing
Open in API
Filings indexed 161 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country US United States of America
Listing US ACTU

About ACTUATE THERAPEUTICS, INC.

https://actuatetherapeutics.com/

Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies for cancers with high unmet medical needs. The company's lead drug candidate is elraglusib, a novel, first-in-class small molecule inhibitor of glycogen synthase kinase-3 (GSK-3). Elraglusib is being developed for difficult-to-treat cancers, including metastatic pancreatic cancer. Its mechanism of action targets multiple molecular pathways involved in promoting tumor growth and resistance to conventional drugs. Additionally, it functions as a mediator of anti-tumor immunity by inhibiting immune checkpoints and regulating immune cell function. The company's goal is to develop therapies that can slow, stop, or shrink tumors with minimal adverse effects, thereby improving patient outcomes.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Form 8-K Current Report under Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing the final voting results from the company’s Annual Meeting of Stockholders. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 English
INITIAL REGISTRATION STATEMENT
Regulatory Filings Classification · 12% confidence The document is a Form S-8 registration statement filed with the U.S. Securities and Exchange Commission to register additional shares under the company’s employee stock incentive plan. It is not an annual or quarterly report, earnings release, proxy statement, or other specific investor presentation. As a form of regulatory filing that does not fit into the more specific categories, it falls under the general Regulatory Filings category.
2026-05-14 English
FORM 10-Q FOR MAR 2026
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
Regulatory Filings Classification · 88% confidence The document is an SEC Form 8-K Current Report under Section 13 or 15(d) of the Exchange Act announcing Regulation FD Disclosure, furnishing a press release and corporate presentation as exhibits. It is a general regulatory announcement and does not contain substantive financial statements or detailed content of the exhibits themselves. Thus it falls under the “Regulatory Filings” category.
2026-05-11 English
8-K - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
Board/Management Information Classification · 98% confidence The document is a Form 8-K Current Report under Item 5.02 which describes the appointment of a new director to the Board and related compensatory arrangements. This is clearly an announcement of a change in the company’s board of directors, fitting the Board/Management Information category.
2026-05-06 English
ARS - ACTUATE THERAPEUTICS, INC. (0001652935) (Filer)
Annual Report
2026-04-09 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.